News & Updates

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

The use of high-dose erythropoietin in the treatment of preterm infants with intraventricular haemorrhage (IVH) does not appear to produce improvements in neurological outcomes, according to a study.

Using a real-time potassium monitoring device saves money and improves quality of life (QoL) in haemodialysis patients in a study presented at Kidney Week 2022.

In children with hypoplastic left heart syndrome, preterm birth appears to be associated with poor right ventricular (RV) remodeling parameters and lower transplant-free survival rates, a new study has found.